Interestingly, a recent study revealed that the effects of atremorine as a dopamine enhancer largely depend on variants in several PD-related genes, including SNCA, LRRK2, DRD2, CYP2D6, NAT2, DAT, and APOE among others [150]. The gene discussed is SLC6A3; the disease is Parkinson disease.